hit counter
Bio-Path Holdings, Inc. (BPTH) Stock News Sentiment & Price - Sentifly
BPTH - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Bio-Path Holdings, Inc. (BPTH)

USA
Drug Delivery
NASDAQ
BPTH Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
BPTH Latest news
GlobeNewsWire
Neutral
Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021
2021-11-05 08:00

HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 12, 2021 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2021 and to provide a business overview.

GlobeNewsWire
Neutral
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
2021-11-04 09:01

HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 11-14, 2021 in Atlanta, GA. In addition, ASH abstracts will appear in the November supplemental issue of Blood.

GlobeNewsWire
Neutral
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors
2021-10-27 07:00

Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Triple Negative Breast Cancer Phase 1/1b Clinical Trial to Evaluate Ability of Prexigebersen-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Triple Negative Breast Cancer

Zacks Investment Research
Neutral
Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug
2021-08-25 11:34

Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients.

InvestorPlace
Positive
BPTH Stock: The Good News That Has BioPath Investors Smiling Today
2021-08-24 13:00

BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today appeared first on InvestorPlace.

InvestorPlace
Positive
BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20%
2021-08-24 11:56

BPTH stock is shooting up this morning as the company reveals a new plan for evaluating the effectiveness of one of its drugs. The post BPTH Stock: Why Little-Known Bio-Path Holding Just Popped More Than 20% appeared first on InvestorPlace.

Benzinga
Positive
Why Bio-Path Holdings Shares Are Surging Higher Today
2021-08-24 11:00

Bio-Path Holdings Inc (NASDAQ: BPTH) is surging higher Tuesday after the company announced the U.S Food and Drug Administration reviewed and cleared its Investigational New Drug application for BP1002 in refractory/relapsed acute myeloid leukemia patients. “AML patients that fail frontline venetoclax-based therapy have very poor prognosis with a median overall survival of less than three months and a novel treatment modality is urgently needed for such patients," said Peter Nielsen, president and CEO of Bio-Path Holdings.

Benzinga
Positive
Why Bio-Path Shares Are Moving Higher In Premarket Tuesday?
2021-08-24 08:15

The FDA has signed off Bio-Path Holdings Inc's (NASDAQ: BPTH) Investigational New Drug (IND) application for BP1002 in refractory/relapsed acute myeloid leukemia (AML) patients. In Phase 1/ 1b trial, six evaluable patients will be treated with BP1002 monotherapy in a standard 3+3 design, with a starting dose of 20 mg/m2.

Pulse2
Positive
Bio-Path Holdings Shares Increase Over 30% Pre-Market: Why It Happened
2021-08-24 07:40

The shares of Bio-Path Holdings, Inc. (NASDAQ: BPTH) increased by over 30% pre-market. This is why it happened.

GlobeNewsWire
Neutral
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
2021-08-24 07:00

Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients Phase 1/ 1b Clinical Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed AML Patients

Loading more news...